A Phase 2 interventional study of Paltusotine and Placebo in Acromegaly, sponsored by Crinetics Pharmaceuticals Inc.. Completed at 11 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-17.
Sponsored by Crinetics Pharmaceuticals Inc. (part of Vertex Pharmaceuticals Incorporated) · Phase 2, Interventional, and Treatment
A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are responders to octreotide LAR or lanreotide depot.
202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.
This study's enrollment of 13 is below the median of 43 across 115 interventional studies indexed under Acromegaly.
Browse Acromegaly studies →Crinetics Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Paltusotine
Drug: Placebo
Paltusotine, capsules, once daily by mouth
Also known as: CRN00808
Placebo, capsules, once daily by mouth
Responder Criteria Was Based on the Mean of Two Consecutive Insulin-like Growth Factor-1 [IGF-1] Measurements ≤ULN at Week 13
Proportion of subjects who meet responder criteria (based on the mean of two consecutive IGF-1 measurements ≤ upper limit of normal \[ULN\])
Time frame: 13 Weeks
Change in IGF-1 Levels
Change in IGF-1 levels between RWP Baseline/Week 10 and Week 13
Time frame: From Week 10 to Week 13
Change in Growth Hormone (GH) Levels
Change in growth hormone levels between RWP Baseline/Week 8 and Week 13
Time frame: From Week 8 to Week 13
Change in Total ASD Score Between RWP Baseline/Week 10 and Week 13
Measured by total Acromegaly symptom diary (ASD) score from W10-W13. ASD is a sponsor-developed daily diary to assess important acromegaly symptoms from the patient perspective. It covers 7 symptoms (headache pain, joint pain, sweating, fatigue, weakness in legs, swelling, and numbness or tingling). Patients rate the severity of each experience in the past 24 hours on an 11-point numeric scale that ranges from 0 (no symptom) to 10 (worst symptom). A weekly average ASD score is calculated for each item as the sum of the item responses for a specific item over the course of the study week divided by the number of days on which the item was completed. The weekly average ASD total score is calculated by computing the sum of the weekly average item scores for the 7 items (total range from 0 to 70), where higher score = higher symptom severity.
Time frame: From Week 10 to Week 13
Medically stable male and female subjects 18 to 75 years of age, inclusive, with a confirmed acromegaly diagnosis that was controlled on a stable approved dose of octreotide LAR or lanreotide depot. At a minimum, there had to be documentation available of a pituitary tumour and elevated IGF-1 in the past.
| Milestone | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Paltusotine | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Placebo | Titration Period: Paltusotine, Then Not Randomized |
|---|---|---|---|
| Started | 3 | 4 | 6 |
| Completed | 3 | 4 | 6 |
| Not completed | 0 | 0 | 0 |
| Milestone | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Paltusotine | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Placebo | Titration Period: Paltusotine, Then Not Randomized |
|---|---|---|---|
| Started | 3 | 4 | 6 |
| Completed | 3 | 4 | 5 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Covid-19 | 0 | 0 | 1 |
| Milestone | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Paltusotine | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Placebo | Titration Period: Paltusotine, Then Not Randomized |
|---|---|---|---|
| Started | 3 | 4 | 5 |
| Completed | 3 | 4 | 0 |
| Not completed | 0 | 0 | 5 |
| Withdrew: Participants who did not meet randomization criteria did not enter the randomized withdrawal period. | 0 | 0 | 5 |
| Milestone | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Paltusotine | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Placebo | Titration Period: Paltusotine, Then Not Randomized |
|---|---|---|---|
| Started | 3 | 4 | 5 |
| Completed | 3 | 3 | 5 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Covid-19 | 0 | 1 | 0 |
Proportion of subjects who meet responder criteria (based on the mean of two consecutive IGF-1 measurements ≤ upper limit of normal \[ULN\])
| percentage of responders | Randomized Withdrawal Period: Paltusotine | Randomized Withdrawal Period: Placebo | Randomized Withdrawal Period: Not Randomized |
|---|---|---|---|
| Responder Criteria Was Based on the Mean of Two Consecutive Insulin-like Growth Factor-1 [IGF-1] Measurements ≤ULN at Week 13 | 66.7 (9.4 to 99.2) | 25.0 (0.6 to 80.6) | 16.7 (0.4 to 64.1) |
Change in IGF-1 levels between RWP Baseline/Week 10 and Week 13
| percent change in IGF1 | Randomized Withdrawal Period: Paltusotine | Randomized Withdrawal Period: Placebo | Randomized Withdrawal Period: Not Randomized |
|---|---|---|---|
| Change in IGF-1 Levels | 4.04 ± 5.064 | 48.17 ± 41.408 | — |
Change in growth hormone levels between RWP Baseline/Week 8 and Week 13
| percent change in GH | Randomized Withdrawal Period: Paltusotine | Randomized Withdrawal Period: Placebo | Randomized Withdrawal Period: Not Randomized |
|---|---|---|---|
| Change in Growth Hormone (GH) Levels | 71.96 ± 48.865 | 108.30 ± 179.977 | — |
Measured by total Acromegaly symptom diary (ASD) score from W10-W13. ASD is a sponsor-developed daily diary to assess important acromegaly symptoms from the patient perspective. It covers 7 symptoms (headache pain, joint pain, sweating, fatigue, weakness in legs, swelling, and numbness or tingling). Patients rate the severity of each experience in the past 24 hours on an 11-point numeric scale that ranges from 0 (no symptom) to 10 (worst symptom). A weekly average ASD score is calculated for each item as the sum of the item responses for a specific item over the course of the study week divided by the number of days on which the item was completed. The weekly average ASD total score is calculated by computing the sum of the weekly average item scores for the 7 items (total range from 0 to 70), where higher score = higher symptom severity.
| Total ASD score change -units on a scale | Randomized Withdrawal Period: Paltusotine | Randomized Withdrawal Period: Placebo | Randomized Withdrawal Period: Not Randomized |
|---|---|---|---|
| Change in Total ASD Score Between RWP Baseline/Week 10 and Week 13 | 1.571 ± 3.1004 | 7.962 ± 7.1591 | — |
Collected over Duration of participation for each subject after obtaining a signed informed consent was up to 23 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Analysis Set/Titration Period - Paltusotine | 0/13 (0%) | 0/13 (0%) | 8/13 (61.5%) |
| Randomized Withdrawal Period - Paltusotine | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Randomized Withdrawal Period - Placebo | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Total Paltusotine | 0/13 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| Event | Safety Analysis Set/Titration Period - Paltusotine | Randomized Withdrawal Period - Paltusotine | Randomized Withdrawal Period - Placebo | Total Paltusotine |
|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/13 | 0/3 | 2/4 | 1/13 |
| HypertensionVascular disorders | 0/13 | 1/3 | 0/4 | 1/13 |
| Blood triglycerides increasedInvestigations | 0/13 | 1/3 | 0/4 | 1/13 |
| HeadacheNervous system disorders | 3/13 | 1/3 | 0/4 | 4/13 |
| FatigueGeneral disorders | 2/13 | 1/3 | 0/4 | 3/13 |
| PainGeneral disorders | 0/13 | 1/3 | 0/4 | 1/13 |
| Back painMusculoskeletal and connective tissue disorders | 0/13 | 1/3 | 1/4 | 1/13 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/13 | 1/3 | 0/4 | 1/13 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 0/13 | 0/3 | 1/4 | 0/13 |
| ParaesthesiaNervous system disorders | 2/13 | 0/3 | 1/4 | 2/13 |
The Baseline Analysis Population includes all subjects who received treatment in the titration period. This includes subjects who were randomized in the randomized withdrawal period to receive placebo or continue receiving paltusotine and subjects who were not randomized and continued receiving paltusotine. The primary endpoint is presented for all subjects. Secondary endpoints are presented only for the randomized subjects as the RW baseline was not applicable to the non-randomized subjects.
| Age, Categorical(Participants) | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Paltusotine | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Placebo | Titration Period: Paltusotine, Then Not Randomized | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 4 | 4 | 9 |
| >=65 years | 2 | 0 | 2 | 4 |
| Age, Continuous(years) | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Paltusotine | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Placebo | Titration Period: Paltusotine, Then Not Randomized | Total |
|---|---|---|---|---|
| Mean | 65.0 ± 3.00 | 38.8 ± 8.66 | 57.7 ± 11.48 | 53.5 ± 13.76 |
| Sex: Female, Male(Participants) | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Paltusotine | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Placebo | Titration Period: Paltusotine, Then Not Randomized | Total |
|---|---|---|---|---|
| Female | 2 | 1 | 3 | 6 |
| Male | 1 | 3 | 3 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Paltusotine | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Placebo | Titration Period: Paltusotine, Then Not Randomized | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 2 | 3 |
| Not Hispanic or Latino | 2 | 4 | 4 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Paltusotine | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Placebo | Titration Period: Paltusotine, Then Not Randomized | Total |
|---|---|---|---|---|
| White | 3 | 4 | 5 | 12 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 1 | 1 |
| UGT1A1 Genotype(Participants) | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Paltusotine | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Placebo | Titration Period: Paltusotine, Then Not Randomized | Total |
|---|---|---|---|---|
| *1/*1 | 1 | 2 | 2 | 5 |
| *1/*80 | 2 | 1 | 2 | 5 |
| *80/*80 | 0 | 1 | 1 | 2 |
| Not reported | 0 | 0 | 1 | 1 |
| UGT1A1 Phenotype(Participants) | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Paltusotine | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Placebo | Titration Period: Paltusotine, Then Not Randomized | Total |
|---|---|---|---|---|
| Normal Metabolizer | 1 | 2 | 2 | 5 |
| Intermediate Metabolizer | 2 | 1 | 2 | 5 |
| Poor Metabolizer | 0 | 1 | 1 | 2 |
| Not reported | 0 | 0 | 1 | 1 |
| Height(cm) | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Paltusotine | Titration Period: Paltusotine, Then Randomized Withdrawal Period: Placebo | Titration Period: Paltusotine, Then Not Randomized | Total |
|---|---|---|---|---|
| Mean | 163.07 ± 8.100 | 181.90 ± 14.461 | 167.73 ± 12.502 | 171.02 ± 13.748 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Jul 2020, 16 months.
Results were first posted in Mar 2025, 4 years 8 months after primary completion. A results delay was requested in Jul 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paltusotine
Crinetics Pharmaceuticals Inc. →